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Running Title: Hemobilia associated with anti-thrombotic therapy  





It is generally accepted that anti-thrombotic therapy increases the risk of 
gastrointestinal bleeding and concurrent therapy with a proton-pump inhibitor is 
a standard treatment for patients receiving aspirin. Thus, much attention has 
been paid to the prevention of gastrointestinal bleeding in such patients. 
However, it should be noted that patients treated with anti-thrombotic therapy 
always carry a risk of hemorrhage from any organs including the gastrointestinal 
tract. Here, we present a case with formation of a common bile duct stone 
caused by hemobilia associated with anti-thrombotic therapy. This case 
suggests that we need to bear in mind a possibility of intrabiliary hemorrhage as 
well as gastrointestinal bleeding in patients receiving anti-thrombotic therapy. 
Patients with the former complication show a variety of symptoms associated 




Anti-thrombotic therapy is widely used for the prevention of heart attack and 
stroke [1 2, 3].  Patients treated with anti-coagulant and/or anti-platelet drugs 
sometimes suffer from gastrointestinal bleeding. Thus, anti-thrombotic therapy 
increases the risk of upper gastrointestinal bleeding and much attention has 
been paid to the prevention of gastrointestinal bleeding associated with 
ant-thrombotic therapy [1, 2, 3]. However, it should be noted that patients treated 
with such therapy always carry a risk of hemorrhage from any organs including 
the gastrointestinal tract. Hemobilia, which is defined as hemorrhage into the 
biliary tract, causes a variety of symptoms associated with gastrointestinal 
bleeding, liver abscess, cholangitis, and obstructive jaundice [4-6]. Causes of 
hemobilia include trauma, gallstones, aneurysma, tumor, and coaguloptahy [4, 
5]. Although spontaneous hemobilia may, like upper gastrointestinal bleeding, be 
caused by administration of anti-coagulant or anti-platelet drugs, little attention 
has been paid to the risk of hemobilia in patients treated with anti-thrombotic 
drugs. Here, we present a case with formation of a common bile duct (CBD) 




A 58-year-old man with a history of acute myocardial infarction (AMI) and 
diabetes mellitus presented to our hospital with fever and general fatigue. Blood 
examination revealed leukocytosis (11400 cells/mm3) and an elevated level of 
serum C-reactive protein (26.2 mg/dL; normal level<0.5). His serum 
hepatobiliary enzyme levels were also elevated (aspartate aminotransferase 53 
IU/L; normal 13-33, alkaline phosphatase 461 IU/L; 129-241, -glutamyl 
transpeptidase 187 IU/L; 9-54). Escherichia coli was detected in his blood. 
Abdominal contrast-enhanced computed tomography, which was performed to 
detect the origin of the infection, revealed a tumor in segment 8 of the liver (Fig. 
1) and a dilated CBD. The liver tumor consisted of a central hypo-dense area 
and peripheral areas with ring-like enhancements; these findings were 
consistent with those of pyogenic hepatic abscess [7]. Endoscopic 
 4 
ultrasonography (EUS) and magnetic resonance cholangiopancreatography 
(MRCP) revealed the presence of a narrow substance without acoustic 
shadowing at the bottom of the dilated CBD (Fig. 2A, B). This finding strongly 
suggested that the normal flow of bile was abrogated by the debris or stone in 
the CBD. Based on these data, the patient was diagnosed as septicemia due to 
liver abscess associated with debris or stone in the CBD. Although the patient 
had no history of gallbladder disease, EUS and MRCP revealed segmental wall 
thickening of fundal and body portions of the gallbladder, suggesting the 
presence of segmental and fundal type adenomyomatosis. The filling defect in 
the CBD was also detected using endoscopic retrograde cholangiography and a 
narrow-long fragile stone with dark brown color was endoscopically removed 
(Fig. 2C). The liver abscess resolved soon after the removal of the CBD stone, 
which suggested that this CBD stone was responsible for the liver abscess 
development. 
 
Since the shape and color of this stone were different from those of the typical 
cholesterol and pigment stones, we analyzed this stone by using infrared 
absorption spectroscopy. Surprisingly, infrared absorption spectroscopy 
revealed that a major component (>98 %) of this stone was protein. The fact that 
this patient had been treated with anti-thrombotic therapy including systemic 
heparinization, after AMI, which occurred 6 months before admission led us to 
consider the possibility that clots originating from an intrabiliary hemorrhage 
caused by anti-thrombotic therapy became compact with increasing bile content 
to inhibit the normal bile flow. To verify this idea, we tried to detect the presence 
of serum proteins such as IgG in the protein extracts from this stone. We 
performed electrophoresis and immuno-blotting as described previously [8]. The 
presence of IgG light chain was confirmed by Coomassie blue staining of the 
blotted membrane when 56 g of isolated proteins was applied to the gel (Fig. 
3A). More importantly, immuno-blotting by using anti-human IgG antibody 
revealed the presence of both heavy and light IgG chains (Fig. 3B). Considering 
that gallstones usually do not contain a significant amount of human IgG, it is 
strongly suggested that the detected IgG originated from serum and that 






Upper gastrointestinal bleeding is often seen in patients treated by 
anti-thrombotic therapy [1, 2, 3]. In contrast, anti-thrombotic therapy causes 
intrabiliary hemorrhage in a very limited number of patients. Thus, it is likely that 
there is a trigger for the development of hemobilia in such patients. Such 
potential triggers include biliary inflammation and invasion of cancer cells into 
the biliary tract [4-6]. In this regard, spontaneous hemobilia is sometimes caused 
by overdoses of anti-platelet and/or coagulant drugs [5], which suggests the 
involvement of decreased coagulability in the development of hemobilia. Indeed, 
this patient had been treated with anti-thrombotic therapy including systemic 
heparinization. Further clinical analysis is required to determine the factors that 
increase the risk of intrabiliary hemorrhage in such patients. 
 
An important finding from this case is that clots that remain in the bile duct may 
serve as a nidus for gallstone formation. We have proved that proteins isolated 
from the narrow substance in CBD contain a significant amount of IgG derived 
from serum. Thus, it is likely that the CBD substance causing liver abscess and 
dilatation of the bile duct originates from clots in this case. Therefore, formation 
of gallstone may be one of the late complications of hemobilia. Although acute 
biliary obstruction by clots sometimes causes fever, epigastralgia, and jaundice 
due to cholangitis, cholecystitis and pancreatitis at the onset of hemobilia [4, 5], 
similar symptoms can occur at a late phase as a result of stone formation. This 
idea is supported by the report on 2 cases of biliary calculi caused by hemobilia 
[9]. Given the fact that serum levels of -glutamyl transpeptidase in this case 
were elevated from two months before the admission, we speculate that clots in 
the bile duct had existed for more than two months in this case. 
 
In conclusion, antithrombotic therapy may increase the risk of hepatobiliary 
diseases by causing hemobilia. We need to bear in mind a possibility of 











Figure 1. Abdominal computed tomography image showing the development of 
liver abscess in segment 8 (arrows).  
 
Figure 2. (A) Magnetic resonance cholangiopancreatography image showing a 
narrow and long substance (arrows) at the bottom of the common bile duct 
(CBD). (B) Endoscopic ultrasonography image showing a narrow substance 
without acoustic shadowing at the bottom of the dilated CBD (arrows). (C) 
Endoscopic removal of a narrow-long fragile stone with dark brown color.  
 
Figure 3. Protein extracts (14, 28, 56 g) isolated from the CBD stone was 
subjected to Coomassie blue staining (A) and immuno-blotting with anti-human 
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